SNTI (Senti Biosciences Holdings) Short Interest


SNTI Senti Biosciences Holdings Inc SNTI
22 GF Score
Price $1.03
! 7 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SNTI vs ALGS, CRVO, NTRB: Short Interest Comparison

For the Biotechnology subindustry, Senti Biosciences Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senti Biosciences Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Senti Biosciences Holdings's Short Interest falls into.


SNTI
22GF Score
Senti Biosciences Holdings Inc SNTI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score

Get the complete analysis for SNTI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price